Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Validation of the UK myeloma research alliance risk profile, a new clinical prediction model for outcome in patients with newly diagnosed multiple myeloma not eligible for autologous stem cell transplantation; a population-based study from the Danish national multiple myeloma registry

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Redder, Louise ; Klausen, Tobias W ; Vangsted, Annette Juul ; Gregersen, Henrik ; Andersen, Niels F ; Pedersen, Robert S ; Szabo, Agoston G ; Frederiksen, Mikael ; Frølund, Ulf C ; Helleberg, Carsten ; Nielsen, Lene Kongsgaard ; Pedersen, Per T ; Salomo, Morten ; Gimsing, Peter ; Frederiksen, Henrik ; Abildgaard, Niels. / Validation of the UK myeloma research alliance risk profile, a new clinical prediction model for outcome in patients with newly diagnosed multiple myeloma not eligible for autologous stem cell transplantation; a population-based study from the Danish national multiple myeloma registry. In: British Journal of Haematology. 2021 ; Vol. 193, No. 1. pp. 119-124.

Bibtex

@article{71782f8d8cda4c8abcab8aaf30dc4886,
title = "Validation of the UK myeloma research alliance risk profile, a new clinical prediction model for outcome in patients with newly diagnosed multiple myeloma not eligible for autologous stem cell transplantation; a population-based study from the Danish national multiple myeloma registry",
abstract = "In 2019 the UK Myeloma Research Alliance introduced the Myeloma Risk Profile (MRP) for prediction of outcome in patients with newly diagnosed multiple myeloma (MM), ineligible for autologous stem cell transplantation. To validate the MRP in a population-based setting we performed a study of the entire cohort of transplant ineligible MM patients above 65 years in the Danish National MM Registry. Our data confirmed the value of the MRP. In a cohort of 1,377 patients, the MRP score separated patients into three distinct risk-groups with an observed hazard ratio of 2.91 for early death in high-risk versus low-risk patients.",
keywords = "Myeloma Risk Profile, geriatric, multiple myeloma, prognosis, survival",
author = "Louise Redder and Klausen, {Tobias W} and Vangsted, {Annette Juul} and Henrik Gregersen and Andersen, {Niels F} and Pedersen, {Robert S} and Szabo, {Agoston G} and Mikael Frederiksen and Fr{\o}lund, {Ulf C} and Carsten Helleberg and Nielsen, {Lene Kongsgaard} and Pedersen, {Per T} and Morten Salomo and Peter Gimsing and Henrik Frederiksen and Niels Abildgaard",
note = "{\textcopyright} 2020 British Society for Haematology and John Wiley & Sons Ltd.",
year = "2021",
month = apr,
doi = "10.1111/bjh.16806",
language = "English",
volume = "193",
pages = "119--124",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "1",

}

RIS

TY - JOUR

T1 - Validation of the UK myeloma research alliance risk profile, a new clinical prediction model for outcome in patients with newly diagnosed multiple myeloma not eligible for autologous stem cell transplantation; a population-based study from the Danish national multiple myeloma registry

AU - Redder, Louise

AU - Klausen, Tobias W

AU - Vangsted, Annette Juul

AU - Gregersen, Henrik

AU - Andersen, Niels F

AU - Pedersen, Robert S

AU - Szabo, Agoston G

AU - Frederiksen, Mikael

AU - Frølund, Ulf C

AU - Helleberg, Carsten

AU - Nielsen, Lene Kongsgaard

AU - Pedersen, Per T

AU - Salomo, Morten

AU - Gimsing, Peter

AU - Frederiksen, Henrik

AU - Abildgaard, Niels

N1 - © 2020 British Society for Haematology and John Wiley & Sons Ltd.

PY - 2021/4

Y1 - 2021/4

N2 - In 2019 the UK Myeloma Research Alliance introduced the Myeloma Risk Profile (MRP) for prediction of outcome in patients with newly diagnosed multiple myeloma (MM), ineligible for autologous stem cell transplantation. To validate the MRP in a population-based setting we performed a study of the entire cohort of transplant ineligible MM patients above 65 years in the Danish National MM Registry. Our data confirmed the value of the MRP. In a cohort of 1,377 patients, the MRP score separated patients into three distinct risk-groups with an observed hazard ratio of 2.91 for early death in high-risk versus low-risk patients.

AB - In 2019 the UK Myeloma Research Alliance introduced the Myeloma Risk Profile (MRP) for prediction of outcome in patients with newly diagnosed multiple myeloma (MM), ineligible for autologous stem cell transplantation. To validate the MRP in a population-based setting we performed a study of the entire cohort of transplant ineligible MM patients above 65 years in the Danish National MM Registry. Our data confirmed the value of the MRP. In a cohort of 1,377 patients, the MRP score separated patients into three distinct risk-groups with an observed hazard ratio of 2.91 for early death in high-risk versus low-risk patients.

KW - Myeloma Risk Profile

KW - geriatric

KW - multiple myeloma

KW - prognosis

KW - survival

UR - http://www.scopus.com/inward/record.url?scp=85086048766&partnerID=8YFLogxK

U2 - 10.1111/bjh.16806

DO - 10.1111/bjh.16806

M3 - Journal article

C2 - 32515050

VL - 193

SP - 119

EP - 124

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 1

ER -

ID: 62109857